lysophosphatidylethanolamine

lipid

Lysophosphatidylethanolamine dysregulation in monocytes and plaques associates with CAD risk, plaque burden, and acute coronary events.

Pathway placement

Cascade stepLipid retention & oxidation

Confidencehigh

RationaleAltered in CAD and AMI; plaque composition modulation; unsaturated species CAD risk.

Also acts inVascular inflammation, Coagulation / thrombus

Druggability

Not assessed (no mapped human gene target).

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma (EDTA to limit oxidation)

Collection tube

K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

LC-MS/MS lipidomics (targeted or shotgun)

Reagent / substrate

Deuterated lipid-class internal standards; MS/MS transitions

Platform

LC-MS/MS

Turnaround · availability

Research · Research-only